The pneumococcus at the millennium: Not down, not out

Journal of Infectious Diseases

Volumn 179, Issue SUPPL. 2, 1999, Pages

  Austrian, Robert ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; PENICILLIN G; PNEUMOCOCCUS VACCINE; SULFONAMIDE;

ANTIBIOTIC RESISTANCE; BACTERIUM ISOLATE; CONFERENCE PAPER; DRUG EFFICACY; IMMUNOPROPHYLAXIS; INFECTION CONTROL; INFECTION RISK; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

EID: 0033381537     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/513841     Document Type: Conference Paper

References (38)

1. 1. Sternberg GM. A fatal form of septicaemia in the rabbit, produced by the subcutaneous injection of human saliva. An experimental research. Natl Board of Health Bull 1881;2:781-3.
2. 2. Pasteur L. Note sur la maladie nouvelle provoquée par la salive d'un enfant mort de la rage. Comptes Rendus 1881;92:159-65.
3. 3. Austrian R. The Gram stain and the etiology of lobar pneumonia, an historical note. Bacteriol Rev 1960;24:261-5.
4. 4. Netter. De l'endocardite végétante-ulcereuse d'origine pneumonique. Arch Physiol Normal Pathol 1886;8(series 3):106-61.
5. 5. Centers for Disease Control and Prevention. Defining the public health impact of drug-resistant Streptococcus pneumoniae. MMWR Morb Mortal Wkly Rep 1996;45(RR-I):1.
6. 6. Heffron R. Pneumonia with special reference to pneumococcus lobar pneumonia. Cambridge, MA: Harvard University Press, 1979:656-63.
7. 7. Klemperer G, Klemperer F. Versuche über Immunisierung and Heilung bei der Pneumokokkeninfection. Berl Klin Wochenschr 1891;28:833-5, 869-75.
8. 8. Neufeld F. Ueber ein specifische bakteriolytische Wirkung der Galle. Z Hyg Infektionskr 1900;34:454-64.
9. 9. Neufeld F, Haendel. Weitere Untersuchungen über Pneumokokken Heilsera. III Mitteilung. Über Vorkommen und Bedeutung atypischer Varietäten des Pneumokokkus. Arb Kaiserlichen Gesundheitsamte 1910;34: 293-304.
10. 10. Neufeld F. Ueber die Agglutination der Pneumokokken and über die Theorie der Agglutination. Z Hyg Infektionskr 1902;40:54-72.
11. 11. Neufeld F, Etinger-Tulczynska R. Schnelldiagnose der Pneumokokkentypen aus dem Auswurf. Z Hyg Infektionskr 1933;115:431-5.
12. 12. Avery OT, Chickering HT, Cole R, Dochez AR. Acute lobar pneumonia, prevention and serum treatment. Monogr Rockefeller Inst 1917;7: 1-110.
13. 13. Beeson PB, Goebel WF. The immunological relationship of the capsular polysaccharide of type XIV pneumococcus to the blood group A specific substance. J Exp Med 1939;70:239-47.
14. 14. Chain E, Florey HW, Gardner AD, et al. Penicillin as a therapeutic agent. Lancet 1940;2:226-8.
15. 15. Morgenroth J, Kaufmann M. Arzneifestigkeit bei Bakterien (Pneumokokken). Z Immuntätsforsch [I] 1912;15:610-24.
16. 16. Moore HF, Chesney AM. A study of ethylhydrocuprein (Optochin) in the treatment of acute lobar pneumonia. Arch Intern Med 1917;19: 611-82.
17. 17. Moore HF, Chesney AM. A further study of ethylhydrocuprein (Optochin) in the treatment of acute lobar pneumonia. Arch Intern Med 1918;21: 659-81.
18. 18. MacLean IH, Rogers KB, Fleming AM. M&B 693 and pneumococci. Lancet 1939;1:562-8.
19. 19. Tillett WS, Cambier MJ, McCormack JE. The treatment of lobar pneumonia and pneumococcal empyema with penicillin. Bull NY Acad Med 1944;20:142-78.
20. 20. Schmidt LH, Sessler CL. Development of resistance to penicillin by pneumococci. Proc Soc Exp Biol Med 1943;52:553-7.
21. 21. Eriksen KR. Studies on induced resistance to penicillin in a pneumococcus type I. Acta Pathol Microbiol Scand 1945;22:398-405.
22. 22. Jacobs MR, Koornhof HJ, Robins-Browne RM, et al. Emergence of multiply resistant pneumococci. N Engl J Med 1978;299:735-40.
23. 23. Eagle H. Speculations as to the therapeutic significance of the penicillin blood level. Ann Intern Med 1948;28:260-77.
24. 24. Gunnison JB, Fraher MA, Pelcher EA, Jawetz E. Penicillin-resistant variants of pneumococci. Appl Microbiol 1968;16:311-4.
25. 25. Hoffman J, Cetron MS, Farley MM, et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995;333:481 -6.
26. 26. Austrian R, Gold J. Pneumococcal bacteremia with special reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964;60: 759-76.
27. 27. Austrian R. Of gold and pneumococci. A history of pneumococcal vaccines in South Africa. Trans Am Clin Climatol Assoc 1977;89:141-61.
28. 28. Wright AE, Parry Morgan W, Colebrook L, Dodgson RW. Prophylactic inoculation against pneumococcal infections, and on the results which have been achieved by it. Lancet 1914;1:1-10, 87-95.
29. 29. Maynard GD. An enquiry into the etiology, manifestations, and prevention of pneumonia amongst natives on the Rand recruited from tropical areas. Publ S Afr Institut Med Res 1913;1:1-101.
30. 30. Lister FS. An experimental study of prophylactic inoculation against pneumococcal infection in the rabbit and in man. Publ S Afr Institut Med Res 1916;8:231-87.
31. 31. Schiemann O, Casper W. Sind die spezifisch präcipitabelen Substanzen der 3 Pneumokokkentypen Haptene. Z Hyg Infektionskr 1927;108: 220-57.
32. 32. Francis TJ Jr, Tillett WS. Cutaneous reactions in pneumonia. The development of antibodies following the intradermal injection of type-specific polysaccharide. J Exp Med 1930; 52:573-85.
33. 33. MacLeod CM, Hodges RG, Heidelberger M, Bernhard WG. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J Exp Med 1945;82:445-65.
34. 34. Austrian R, Douglas RM, Schiffman G, et al. Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians 1976;89: 184-92.
35. 35. Hodges RG, MacLeod CM, Bernhard WG. Epidemic pneumococcal pneumonia. III. Pneumococcal carrier studies. Am J Hyg 1946;44:207-30.
36. 36. Thomsen O, Kettel K. Die Stärke der menschlichen Isoagglutine und entsprechender Blutkörperchenrezeptoren in verschiedenen Lebensaltern. Z Immunitätsforsch Exp Ther 1929;63:67-93.
37. 37. Miller RA. The aging immune system. Science 1996;273:70-4.
38. 197 vaccines: effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines. J Infect Dis 1997;176:445-55.